Top-line data are expected by the end of 2014...Proceeds would be used to fund clinical trials, R&D for additional alpha-1 antitrypsin (AAT) indications, expanding distribution capabilities for additional territories

The funds will support clinical work in multiple sclerosis (MS), inflammatory bowel disease (IBD) and allergic/immune-mediated disorders. (See BioWorld Today, April 8, 2013.) The pricing hits pretty close to the $86.3 million target set when the company filed for its offering only a month ago...Top-line results from that trial are due in mid-2014

These data led to Eleven's Phase Ib clinical study of EBI-005 in subjects with dry eye disease, with top-line data from the Phase Ib study expected in the second half of 2013

The NH004-3 clinical trial is a double-blind, placebo-controlled, randomized, crossover, multicenter study comparing NH004 and placebo thin films in Parkinson's disease patient complaining of sialorrhea...The study will include 20 subjects, and top-line data are expected by year-end

Esperion disclosed top-line results from this trial in January 2013...clinical trials where a single dose of NX-1207 has been found to produce on average symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs

Top-line data are expected in the fourth quarter...Ltd., of Germantown, Md., said it filed an investigational new drug application (IND) to begin clinical trials of its adipose-derived stem cell product, RNL-JointStem, for the treatment of osteoarthritis

The following data were reported from European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Berlin...In addition to the detailed efficacy and safety results of the ESTABLISH-2 study, which build upon the top-line results previously announced, Trius presented the results of a drug interaction clinical study demonstrating that tedizolid phosphate did not increase blood pressure when used in conjunction with vasoconstrictor drugs such as decongestants...The results of a

Chimerix Inc., of Durham, N.C., presented the first clinical outcomes data on lead candidate CMX001 in life-threatening infection with adenovirus (AdV), a disease with no approved therapy...The company expects to report top-line results in mid-2014

Ceregene Inc., of San Diego, reported top-line data from its double-blind, randomized, controlled Phase IIb study of CERE-120 (AAV-neurturin), a gene therapy designed to deliver the neurotrophic factor neurturin, for Parkinson's disease...Civitas Therapeutics Inc., of Chelsea, Mass., disclosed positive top-line results from a Phase II trial of CVT-301, an inhaled formulation of levodopa (L-dopa

Alkermes Inc., of Dublin, Ireland, said top-line data from a Phase II study showed that ALKS 5461, a drug in development to treat patients who have an inadequate response to standard therapies for clinical depression, significantly reduced depressive symptoms across a range of standard measures, including the study's primary outcome measure, the Hamilton Depression Rating Scale (p = 0.026), the Montgomery-Asberg Depression Scale (p = 0.004) and the Clinical Global Impression-Severity Scale (p

Reviva Pharmaceuticals Inc., of San Jose, Calif., reported top-line results from its Phase II REFRESH study of RP5063 in schizophrenia and schizoaffective disorder, with the dopamine serotonin stabilizer showing overall broad efficacy across the Positive and Negative Syndrome Scale total scores, as well as subscales: Positive, Negative and General Psychopathology...RP5063 also showed efficacy in the Clinical Global Impression Severity Scale and was well tolerated

Top-line results from that trial are due in mid-2014...Funds will be used to progress the clinical development program for lead candidate, Pracinostat, its oral histone deacetylase inhibitor for advanced hematologic malignancies, and for other general corporate purposes

Array BioPharma Inc., of Boulder, Colo., reported clinical data at the International Myeloma Workshop in Kyoto, Japan, showing that ARRY-520, a selective KSP inhibitor, demonstrated single-agent activity in heavily pretreated patients with relapsed or refractory multiple myeloma, with 19 months median overall survival and a 16 percent overall response rate...Navidea Biopharmaceuticals Inc., of Dublin, Ohio, disclosed top-line results from the interim analysis of its Phase III trial, NEO3-06, of the

Novavax Inc., of Rockville, Md., said top-line data from its Phase II dose-ranging study testing its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age hit its protocol-specified objectives, supporting progression to the next stage of advanced clinical testing

Auxilium Pharmaceuticals Inc., of Chesterbrook, Pa., reported positive top-line data from a Phase IIa trial of Xiaflex (collagenase clostridium histolyticum, or CCH) in adhesive capsulitis, commonly known as frozen shoulder syndrome (FSS...Trius Therapeutics Inc., of San Diego, reported top-line results from its ESTABLISH 2 Phase III study of tedizolid phosphate (TR-701) in acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA

The Phase I/II trial showed a significantly slower decline in overall clinical and respiratory function, as measured by the ALS functional rating score (ALSFRS-R) and forced vital capacity (FVC) score, respectively, in the six patients who received an intrathecal injection of the cells in the six months following treatment, as compared to the three months preceding treatment...Teva Pharmaceutical Industries Ltd., of Jerusalem, and Active Biotech AB, of Lund, Sweden, reported top-line results from

and Europe, with top-line results due in the second half of 2013...MethylGene Inc., of Montreal, reported top-line results from a trial of MGCD290 in combination with fluconazole for vulvovaginal candidiasis

In conjunction with the changes in its clinical program, the company said it reduced its work force by 50 percent and outsourced noncritical research and development functions...Top-line data from the RA study are expected midyear

The study also has exploratory endpoints for clinical efficacy and inflammation biomarkers...Avaxia expects to report top-line results by year-end